Concord Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Concord Biotech has a total shareholder equity of ₹15.3B and total debt of ₹97.4M, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are ₹17.0B and ₹1.7B respectively. Concord Biotech's EBIT is ₹4.0B making its interest coverage ratio -395.1. It has cash and short-term investments of ₹2.8B.
Key information
0.6%
Debt to equity ratio
₹97.38m
Debt
| Interest coverage ratio | -395.1x |
| Cash | ₹2.82b |
| Equity | ₹15.27b |
| Total liabilities | ₹1.74b |
| Total assets | ₹17.01b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: CONCORDBIO's short term assets (₹9.0B) exceed its short term liabilities (₹1.4B).
Long Term Liabilities: CONCORDBIO's short term assets (₹9.0B) exceed its long term liabilities (₹319.1M).
Debt to Equity History and Analysis
Debt Level: CONCORDBIO has more cash than its total debt.
Reducing Debt: Insufficient data to determine if CONCORDBIO's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: CONCORDBIO's debt is well covered by operating cash flow (2726.2%).
Interest Coverage: CONCORDBIO earns more interest than it pays, so coverage of interest payments is not a concern.